HSBC/CALL/GILEAD SCIENCES/120/0.1/19.06.24 | Real-time BOERSE MUENCHEN 11:36:21 31/05/2024 am IST | ||
| 0.016 EUR | 0.00% |
|
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
| Date | Price | Change |
|---|---|---|
| 31/24/31 | 0.016 | 0.00% |
| 30/24/30 | 0.016 | 0.00% |
| 29/24/29 | 0.016 | 0.00% |
| 28/24/28 | 0.016 | 0.00% |
| 27/24/27 | 0.016 | 0.00% |
Real-time BOERSE MUENCHEN
Last update May 31, 2024 at 11:36 am IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | HSBC |
| WKN | HG6MQD |
| ISIN | DE000HG6MQD6 |
| Date issued | 02/11/2022 |
| Strike | 120 $ |
| Maturity | 19/06/2024 (20 Days) |
| Parity | 10 : 1 |
| Emission price | 0.17 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.35 € |
|---|---|
| Lowest since issue | 0.016 € |
| Spread | 0.015 € |
| Spread % | 93.75% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
64.08
USD
Average target price
82.77
USD
Spread / Average Target
+29.17%
- Stock Market
- Warrants
- Warrant
